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Abstract
The normal cornea is devoid of lymphatic and blood vessels, thus suppressing both the afferent 
(lymphatic) and efferent (vascular) arms of the immune response–contributing to its ‘immune 
privilege’. Inflammation, however, negates this unique ‘immune’ and ‘angiogenic’ privilege of the 
cornea. Abnormal blood vessel growth from pre-existing limbal vessels into the cornea has been 
studied for many years, but it is only recently that the significance of new lymphatic vessels 
(lymphangiogenesis) in ocular inflammatory diseases has been demonstrated. Whereas blood 
vessels in inflamed ocular surface provide a route of entry for immune effector cells to the cornea, 
lymphatics facilitate the exit of antigen-presenting cells and antigenic material from the cornea to 
regional lymph nodes, thus promoting induction of adaptive immune response. This review 
summarizes the current evidence for lymphangiogenesis in the cornea, and describes its molecular 
mediators; and discusses the interface between corneal lymphangiogenesis and adaptive immunity. 
Furthermore, the pathophysiologic implications of corneal lymphangiogenesis in the setting of 
allo- and autoimmune-mediated corneal inflammation are discussed.
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Introduction
The lymphatic vasculature plays an important role in the maintenance of fluid homeostasis, 
regulation of lipids, and trafficking of antigen-presenting cells from peripheral tissue to 
regional draining lymph nodes. In contrast to other tissues, the cornea is unique in that it 
actively maintains an avascular and alymphatic state, which limits antigen-presentation and 
leads to its status as an immune privileged tissue. However, the cornea’s immune privilege 
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tcan be disrupted, and blood as well as lymphatic vessels can develop in a number of 
pathologic conditions [1].
The cornea is circumferentially surrounded by lymphatic vessels located in the limbus [2]. 
These vessels connect to the conjunctival lymphatic network but, under homeostatic 
conditions, do not enter the cornea (Figure 1A). Under inflammatory conditions, however, 
these lymphatic vessels can give rise to new lymphatics, which do extend into the cornea 
(Figure 1B) [3]. Blood and lymphatic vessel formation, as in other tissues, is primarily 
mediated by the vascular endothelial growth factor (VEGF) family, with lymphatic vessel 
formation specifically coordinated by the interactions of VEGF Receptor-3 with its ligands, 
VEGF-C and VEGF-D [4]. Activation of VEGFR-3 by VEGF-C leads to phosphorylation of 
protein kinase B (AKT) and extracellular signal-regulated kinase (ERK), which in turn leads 
to lymphatic endothelial cell proliferation and lymphatic tube formation [5,6]. In addition to 
VEGF-C/D signaling through VEGFR-3, additional factors known to promote 
lymphangiogenesis include angiopoietin-2 and integrin alpha 5. Studies inhibiting both type 
of factors have demonstrated efficacy in preferentially blocking corneal lymphangiogenesis 
versus hemangiogenesis [7–9].
Corneal lymphatic vessels may also be able to develop de novo, independent of limbal 
lymphatics. Under inflammatory conditions CD11b+ macrophages in the corneal stroma 
have been observed to express the ‘classic’ lymphangiogenic markers Lymphatic Vessel 
Endothelial Receptor 1 (LYVE-1) and Prospero homeobox 1 (PROX-1). Interestingly, in 
vitro, macrophages are able to aggregate into tube-like structures, which express the 
lymphatic markers LYVE-1 and podoplanin, suggesting a direct contribution of these cells 
to lymphatic vessels. Further, macrophages contribute to the maintenance of corneal 
lymphatics in inflammation [10]. The majority of the lymphatic vasculature develops from 
homeobox gene PROX-1–expressing cells of the venous circulation during embryogenesis, 
which then undergo further remodeling [11]. PROX-1 expression is critical for the initial 
formation of lymphatic endothelial cells from venous cells [12]. Lymphatic endothelial cells 
interlock in two distinct patterns to form lymphatic capillaries in peripheral tissue. 
Lymphatic endothelial cells in initial lymphatics are connected by discontinuous adhesion 
proteins called “buttons”, which are able to create openings through which fluid and 
immune cells can enter. Lymphatic endothelial cells in collecting lymphatics are 
continuously attached in a “zipper”-like fashion [13,14].
In this review we aim to (i) describe the evidence of corneal lymphangiogenesis, (ii) outline 
its molecular mediators, and the interaction between corneal lymphangiogenesis and 
adaptive immunity, and (iii) discuss the pathophysiologic implications of corneal 
lymphangiogenesis in the setting of allo- and autoimmune-mediated corneal inflammation.
Corneal Angiogenic Privilege
A pristine visual axis is of the utmost importance to preserve proper visual function [15]. 
Accordingly, under homeostatic conditions, the cornea is both alymphatic and avascular. 
The importance of this “angiogenic privilege” is emphasized by the presence of multiple 
mechanisms that serve to maintain it.
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tOne mechanism that helps to keep the cornea alymphatic and avascular is through 
controlling the expression and availability of VEGF receptors and ligands, which is 
accomplished through the expression of several anti-angiogenic factors. The corneal 
epithelium expresses a soluble form of VEGFR-3, which acts as a decoy receptor and binds 
VEGF-C and VEGF-D [5,16], as well as soluble VEGFR-2, which prevents lymphatic 
invasion of the central cornea [17]. The cornea also expresses thrombospondin-1, which is 
known to regulate the production of VEGF-C by monocytes/macrophages through binding 
of CD36 [18]. The corneal epithelium additionally expresses soluble VEGFR1, which limits 
hemangiogenesis by acting as a decoy receptor for VEGF-A [19]. Other anti-angiogenic 
factors known to be expressed by the cornea include Pigment epithelium-derived factor 
(PEDF), a potent inhibitor expressed by the corneal epithelium [20,21] as well as 
angiostatin, which is also expressed by the corneal epithelium and is capable of binding 
multiple targets on vascular endothelial cells to inhibit proliferation and migration [22–26]. 
The corneal epithelium also expresses endostatin, which can inhibit angiogenesis by directly 
inhibiting vascular endothelial cell proliferation or by blocking VEGFR-2 signaling [27,28].
The avascular/alymphatic (angiogenic privilege) state of the cornea is intricately linked to its 
immune privileged state, which is maintained among other factors by the expression of a 
range of immunoregulatory factors [29–31]. These anti-inflammatory factors in turn 
contribute to immune and angiogenic privilege by regulating the functional interface 
between immune and vascular endothelial cells. For example, Transforming growth factor 
(TGF)-β2 regulates dendritic cell maturation [32] and the corneal epithelium expresses Fas 
ligand (FasL), which induces apoptosis of FAS-expressing immune cells [33]. Fas is also 
expressed by neovessels arising under inflammatory conditions, but not quiescent vessels, 
meaning that Fas/FasL interactions also have a direct anti-angiogenic effect [34]. 
Programmed death-ligand 1 (PDL-1) is another regulatory molecule expressed constitutively 
at high levels by the corneal epithelium that downregulates T cell responses and induces 
immune cell apoptosis [32, 35]. PDL-1 is also expressed by vascular endothelial cells and its 
inhibition leads to a significant increase in cell proliferation [36].
Additional factors contributing to corneal immune privilege include the general anti-
inflammatory proteins Interleukin (IL)-10 [37] and IL-1Ra. IL-1Ra inhibits pro-
inflammatory IL-1α and IL-1 β by competitively binding IL-1R without inducing signaling 
[38]. By down-regulating inflammation these factors preserve expression of the corneal 
epithelium derived anti-angiogenic factors and prevent the recruitment and activation of 
immune cells such as neutrophils, macrophages, and T cells, all of which promote heme- 
and lymphangiogenesis by secreting VEGF ligands [39–42].
Mechanisms of Corneal Lymphangiogenesis
Loss of corneal angiogenic privilege is due to a deficit in the cornea’s anti-angiogenic 
factors relative to pro-angiogenic factors, and is evident in a number of pathologic 
conditions, including trauma, infection, corneal transplant rejection, and dry eye disease 
[1,43]. Although the inciting injury or disease may vary, the formation of lymphatic vessels 
allows the host to accomplish the same task, namely controlling tissue injury and 
inflammation by facilitating antigen-presenting cell trafficking to regional lymphoid tissues 
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twhere T cell responses can be orchestrated. In contrast, lymphangiogenesis may also 
directly contribute to the resolution of inflammation by clearing cells and debris generated 
as a result of inflammation-induced tissue injury [44,45]. Indeed, in some situations anti-
lymphangiogenic therapy has been observed to actually delay the resolution of inflammation 
[46].
Injury to the cornea, including mechanical trauma and chemical burn, generates a non-
specific inflammatory response driven by the innate immune system. As part of this 
response, damaged corneal tissue produces pro-inflammatory factors, including Tumor 
necrosis factor (TNF)-α, IL-1, chemokines such as CC chemokine ligand (CCL) 2 and 
CCL20, and integrins such as Intercellular Adhesion Molecule 1 (ICAM-1) [40,47–49]. 
These factors not only damage the ocular surface, but also facilitate the recruitment of innate 
immune cells including neutrophils and macrophages, which promote lymphangiogenesis 
through production of VEGF-C and VEGF-D [39,42,50].
Pathologic blood and lymphatic vessels are also commonly seen in infectious processes such 
as herpes simplex viral (HSV) keratitis. Lymphatic vessel formation in HSV infected 
corneas is stimulated by the contributions of the general pro-inflammatory factors described 
above, as well as by the virus itself, which stimulates corneal epithelial cells to drive 
lymphangiogenesis through VEGF-A/VEGFR-2 signaling [51]. In addition, CD8+ T cells 
generated as part of the adaptive immune response to HSV also contribute to 
lymphangiogenesis through their production of VEGF-C [52].
Along with infection, corneal transplant rejection and dry eye disease are two other common 
conditions in which lymphangiogenesis is present and plays an important role. Corneal 
transplantation is the most common form of solid tissue transplantation, with over 100,000 
transplants performed globally each year (as published by the Eye Bank Association of 
America-EBAA). Dry eye disease is a chronic, immunoinflammatory disorder of the ocular 
surface, which affects millions of individuals [53,54]. In both corneal transplantation and 
dry eye disease, lymphangiogenesis permits APCs to reach the draining lymph nodes where 
they then prime naïve T cells and induce a T-helper response. These T cells then traffic back 
to the cornea where they mediate graft rejection or drive the chronic ocular surface 
inflammation seen in dry eye disease.
Corneal Lymphatics as Inducers of Adaptive Immunity
One of the major functions of the lymphatic vasculature in all tissues is to facilitate adaptive 
immunity. Lymphatic vessels are crucial to the host’s ability to respond to infectious agents 
and target antigens, as they facilitate the trafficking of antigen-presenting cells (APCs) to 
draining lymph nodes where they present antigen to naïve T cells. In the case of most 
microbial infections, induction of an adaptive immune response is crucial to the host’s 
ability to defend itself. However, in some cases, adaptive immunity may not be as 
beneficial, as is seen in autoimmune conditions such as multiple sclerosis, rheumatoid 
arthritis, and dry eye disease [53,55,56]. In these conditions, an adaptive immune response is 
inappropriately mounted, leading to destruction of normal tissue and chronic inflammation. 
The adaptive immune response can be similarly detrimental in the setting of organ 
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ttransplantation, as the host immune system sees transplanted tissue as foreign, leading to 
induction of allo-reactive T cells and subsequent rejection of the transplant.
The alloimmune response can be visualized as consisting of afferent and efferent arms 
(Figure 2). Lymphatic vessels mediate the afferent arm of the immune system by facilitating 
the migration of APCs and alloantigens to the draining lymph nodes, where they prime 
alloreactive effector T cells, which then migrate back to the graft via blood vessels (the 
efferent arm). The afferent arm begins with functional changes in lymphatic endothelial cells 
and APCs in response to inflammatory cytokines. Due to inflammation immature APCs 
adopt a mature phenotype, which includes upregulation of major histocompatibility complex 
II and costimulatory molecules [57], as well as downregulation of the chemokine receptors 
CC chemokine receptor (CCR)1, CCR2, CCR5, and chemokine (C-X-C motif) receptor 1 
(CXCR1) as well as upregulation of CCR7 [58,59]. These APCs then enter lymphatic 
capillaries, a process that relies on CCR7+ APCs following a CCL21 gradient, as well as the 
interplay of ICAM-1 and vascular cell adhesion molecule 1 (VCAM-1) and their ligands 
[60–63]. Upon reaching the parafollicular cortex, APCs then present antigen to naïve T 
cells, which differentiate into CD4+ T cells, the predominant effector cells in corneal 
transplantation [64,65].
The importance of lymphatic vessels in alloimmunity is illustrated by the high rate of 
rejection seen in those transplants performed in corneal beds with pre-existing lymphatics, 
so called ‘high-risk’ hosts [66–68]. In these hosts, with a luxurious supply of lymphatics in 
the recipient graft bed, APC trafficking and allo-sensitization is significantly increased 
compared to low-risk hosts with an avascular cornea, and can begin almost immediately; 
APCs are detectable in the draining lymph nodes at 4 hours after transplantation [69], and 
peak at 24 hours post transplantation [70]. Further, the effector T cell response is 
significantly increased in ‘high-risk’ hosts up to 72 hours post transplantation [71]. Several 
anti-lymphangiogenic therapies have shown promise in improving corneal transplant 
survival, including the neutralization of VEGF-C [72] and using a VEGFR-3 trap [73]. Anti-
lymphatic therapy has also been used to improve high-risk corneal transplant outcomes [67]. 
In this study, high-risk host beds were treated with anti-lymphatics prior to transplantation in 
order to reduce lymphatic vessel density. These studies further highlight the importance of 
lymphangiogenesis in alloimmunity, although the utility of anti-lymphatic therapy in the 
clinical setting remains to be seen.
Corneal Lymphatics as Responders of Adaptive Immunity
The formation of new lymphatic vessels is a dynamic process during embryogenesis but is 
relatively rare and selectively regulated in adulthood. Inflammation is the main physiologic 
event that evokes formation of new lymphatic vessels in adulthood [74,75]. It is generally 
recognized that early innate immune responses play a crucial role in the induction of 
lymphangiogenesis in most corneal inflammatory disorders, including transplant rejection 
and infection, which in turn facilitate migration of APCs toward the draining lymphoid 
tissues to prime naïve T cells leading to an adaptive immune response. Innate inflammation 
triggers lymphangiogenesis via early surge of pro-inflammatory molecules that orchestrates 
the inflammatory response, which in turn upregulates expression of vascular growth factors 
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tand cytokines promoting survival, migration, and proliferation of lymphatic endothelial cells 
[76–78]. However, recent studies have demonstrated that not only innate inflammatory 
responses, but also late adaptive immune responses, can play a critical role in the induction 
of lymphangiogenesis in chronic inflammatory conditions such as malignancy and 
autoimmune disorders [79,80].
In a model of T-helper-17 cell (Th17)-dominant autoimmune dry eye disease, we have 
recently reported the selective occurrence of corneal lymphangiogenesis and significantly 
elevated homing of mature APCs to the lymphoid tissues where they induce autoreactive 
IL17+CD4+T cell (Th17) responses [81,82]. Dry eye disease, which is the most common 
ophthalmic pathological condition, is a complex, multifactorial, immune-mediated disorder 
in which chronic ocular surface inflammation is sustained by ongoing activation and 
infiltration of pathogenic immune cells, primarily Th17 cells [83]. We have demonstrated 
that lymphangiogenesis, without concurrent growth of blood vessels (hemangiogenesis), 
occurs in the cornea of mice with dry eyes [81]. Interestingly, along with the progression of 
the disease, these lymphatics not only grow toward the central cornea, but also show 
significantly increased caliber compared to those restricted to the limbal areas of normal 
corneas (Figure 3). This is in contrast to other robust models of corneal inflammation such 
as transplantation or infection where there is either parallel outgrowth of blood and 
lymphatic vessels, or the blood vessels are precedent over the lymphatics [66–68]. New 
ingrowth of lymphatics in dry eye corneas not only provides a link between chronic ocular 
surface inflammation and the generation of T cell mediated immunity in the lymphoid 
compartment, but also offers an example of how lymphangiogenesis and hemangiogenesis 
can be ‘naturally’ dissociated in a pathological state.
Our studies of the cornea in dry eyes have revealed that these corneas significantly up-
regulate pro-lymphangiogenic VEGF-C and VEGF-D along with their receptor VEGFR-3, 
suggesting that the low-grade chronic inflammation seen in dry eyes is selectively conducive 
for lymphangiogenesis. Th17 cells, in addition to their proinflammatory functions, have 
been recognized as potent inducers of angiogenesis in autoimmune diseases and 
malignancies [79,80], but little was known about their function as inducers of lymphatic 
growth. In dry eye disease Th17 cell-secreted IL-17 promotes a selective ingrowth of new 
corneal lymphatic vessels (Figure 4) by inducing increased expression of pro-
lymphangiogenic VEGF-D and VEGF-C by epithelial, stromal and resident immune cells in 
the cornea that can induce proliferation of lymphatic endothelial cells [80]. Importantly, we 
showed that in vivo blockade of IL-17 in dry eye disease significantly reduces corneal 
lymphangiogenesis and the progression of clinical disease. Taken together, these findings 
suggest that in addition to causing corneal damage, Th17 cell-secreted IL-17 promotes the 
growth of corneal lymphatic vessels in autoimmune dry eye disease. Despite the fact that 
innate immunity plays a crucial role in inducing lymphangiogenesis, ingrowth of lymphatic 
vessels in dry eye corneas indicate a new adaptive immune Th17/IL17-mediated mechanism 
in inducing lymphangiogenesis.
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tConclusions
The absence of lymphatic vessels contributes significantly to the immune privileged state of 
the cornea by blunting ocular antigen and APC trafficking to the draining lymph nodes, and 
thus the induction of adaptive immunity. Injury and inflammation, however, can induce 
lymphangiogenesis and result in loss of immune privilege, allowing immune responses in 
the cornea. Complex cellular and molecular mechanisms regulate lymphangiogenesis in 
diverse corneal inflammatory conditions, and only recently, data provide evidence for 
important functional interactions between corneal lymphangiogenesis and the adaptive 
immune response in autoimmunity. In most corneal inflammatory diseases 
lymphangiogenesis is closely linked to hemangiogenesis—together they serve as major 
routes of induction and expression of adaptive immunity such as alloimmune response, 
which is critical in transplant rejection. However, in chronic autoimmune ocular surface 
inflammation such as dry eye disease, there is an exclusive growth of corneal lymphatics 
(without blood vessels), which primarily occurs in response to a Th17-mediated 
autoimmune response. Last, the cornea serves as an ideal site for angiogenic studies (as well 
as vascular endothelial cell-immune cell interactions) due to its accessible location, 
transparent nature, and its blood vessel- and lymphatic-free character. Understanding the 
mechanisms underlying corneal lymphangiogenesis will likely aid in developing more 
specific therapeutic strategies of broader clinical conditions beyond the treatment of corneal 
inflammatory conditions alone.
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Angiogenic privilege of cornea. [A] Normal cornea is a blood and lymphatic vessel-free 
tissue. Vessels are restricted only to the periphery of the cornea (limbal area). [B] In 
response to inflammation, this “angiogenic” privilege of the cornea can be lost leading to the 
ingrowth of both blood and lymphatic vessels. Micrographs from a mouse corneal 
micropocket model of neovascularization show that pellets containing the inflammatory 
cytokine IL-1β robustly induce ingrowth of both new blood (CD31+LYVE1−) and lymphatic 
(LYVE1+CD31lo) vessels. (L: Limbus; P: Pellet).
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Function of lymphatic and blood vessels in corneal alloimmunity. Lymphatics (afferent arm 
of immune system) transport antigens and antigen-presenting cells (APCs) from the graft 
site to the draining lymph nodes, where T cells are primed and expanded. Alloreactive T 
cells return to the cornea via blood vessels (efferent arm) and mediate transplant rejection.
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Selective ingrowth of corneal lymphatic vessels in dry eye disease. Confocal micrographs 
showing corneal lymphangiogenesis in normal cornea and in dry eye corneas at days 6, 10, 
and 14 post-induction of dry eye in a mouse model of dry eye disease. The lymphatic vessels 
(LYVE1+CD31lo) increase both in area and caliber, and grow towards the cornea center 
with disease progression. The lymphatics are unaccompanied by blood vessels (CD31hi/
LYVE1−). (Lymphatics marked by arrows; C: Cornea; L: Limbus). Adapted from [81].
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Mechanism of T-helper-17 (Th17) cell-mediated lymphangiogenesis. Th17 cell-secreted 
interleukin-17 (IL-17) induces lymphangiogenesis via a vascular endothelial growth factor 
(VEGF)-D/C–VEGFR-3 signaling pathway. In response to Th17-secreted IL-17, IL-17-
receptor-expressing cells such as epithelial and stromal cells directly upregulate expression 
of VEGF-D; whereas VEGF-C expression is upregulated via IL-17-induced IL-1β-mediated 
pathway. Both VEGF-D and VEGF-C bind to VEGFR-3 on lymphatic endothelial cells and 
promote proliferation and tube formation by lymphatic endothelial cells.
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